Resin Based sealer
Phase 2Small molecule
Resin Based sealer is one of 31 small molecule programs targeting Pulpitis. It is currently in Phase 2.
1
Indications
2
Total Trials
2
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
50 competitors in Pulpitis
#DrugCompanyPhaseTrials
1Toradol
RocheApproved
Decadron
QQuince Therapeutics S.p.A.
Approved
Tylenol
KKenvue Brands
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Marcaine
IInnocoll
Approved
Osmitrol
BB. Braun Medical Inc.
Approved
Medrol
PfizerPhase 3
Advil
KKenvue Brands
Phase 3
Adrenaline
SSamson Clinical Operations Pty Ltd
Phase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Treatment1 trial
Comparative Evaluation of Post Obturation Pain After Root Canal Treatment Using Tricalcium Silicate vs Resin-Based Sealers
Not yet recruiting·—·N/A·NCT07388368·118 enrolled
Pulpitis1 trial
Postoperative Pain Comparison of Two Root Canal Sealers in Irreversible Pulpitis
Recruiting·—·Phase 2·NCT06975761·62 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Resin Based sealer. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details